scholarly journals Effects of exercise using a mobile device on cardiopulmonary function, metabolic risk factors, and self-efficacy in obese women

2018 ◽  
Vol 14 (5) ◽  
pp. 829-834 ◽  
Author(s):  
Dae-Young Kim
Keyword(s):  
Risk Factors ◽  
Mobile Device ◽  
Self Efficacy ◽  
Metabolic Risk Factors ◽  
Metabolic Risk ◽  
Obese Women ◽  
Cardiopulmonary Function

Interleukin-6 G-174C gene polymorphism and serum resistin levels in North Indian women: Potential risk of metabolic syndrome

2010 ◽  
Vol 30 (10) ◽  
pp. 1445-1453 ◽  
Author(s):  
A Gupta ◽  
V Gupta ◽  
AK Singh ◽  
S Tiwari ◽  
S Agrawal ◽  
...  
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Genetic Polymorphism ◽  
Interleukin 6 ◽  
Metabolic Risk Factors ◽  
Metabolic Risk ◽  
Obese Women ◽  
Resistin Level ◽  
Indian Women ◽  
Mutant Genotype

The present investigations were aimed to identify the possible association between genetic polymorphism in interleukin-6 (IL-6) G-174C gene, which confers susceptibility to metabolic syndrome, and serum level of resistin in North Indian women. The study population comprised 370 unrelated Indian women (192 having abdominal obesity and 178 controls). Polymorphism in genotype (CC+GC) of IL-6 G-174C gene was determined using a combination of polymerase chain reaction (PCR) and sequence-specific primer with restriction fragment length polymorphism (RFLP) technology. Insulin resistance (IR) and serum resistin level were also analyzed along with metabolic risk factors. Of 192 abdominal obese women, 147 (76.56%) were found to have mutant CC+GC ( p = 0.001) genotype and allele frequency ( p = 0.001), which was significantly higher 45 (23.44%) than non-obese and their respective wild type. The mutant genotype (CC+GC) of IL-6 gene was found to be associated significantly with high triglyceride ( p = 0.025) and resistin level ( p < 0.001), when compared with respective wild genotype (GG) in obese women. Non-obese women with no signs of metabolic risk factors were found to have significantly low level of serum resistin and IR in comparison to obese women having genetic polymorphism for IL-6 G-174C gene. Study suggests that IL-6 G-174C gene is one among the susceptibility loci for metabolic syndrome in North Indian women. Genotype for this polymorphism may prove informative for prediction of genetic risk for metabolic syndrome. Further, high level of serum resistin molecules may be targeted to correlate with metabolic syndrome risk factors and could be used as early prediction marker.

Feasibility of a Home-Based Exercise Program in Lung and Liver Transplant Recipients for Management of Post-Transplant Metabolic Syndrome: A Pilot Randomized Controlled Trial (Preprint)

2021 ◽  
Author(s):  
Dmitry Rozenberg ◽  
Daniel Santa Mina ◽  
Sahar Nourouzpour ◽  
Encarna Camacho Perez ◽  
Brooke Stewart ◽  
...  
Keyword(s):  
Risk Factors ◽  
Resistance Training ◽  
Self Efficacy ◽  
Intervention Group ◽  
Exercise Program ◽  
Metabolic Risk Factors ◽  
Metabolic Risk ◽  
Transplant Recipients ◽  
Post Transplant ◽  
Home Based

BACKGROUND Post-transplant metabolic syndrome (PTMS) is a common contributor to morbidity and mortality in solid organ transplant recipients in the late post-transplant period (≥ 1-year). Patients diagnosed with PTMS are at higher risk of cardiovascular disease and frequently experience decreased physical function and health-related quality of life (HRQL). Studies in the early post-transplant period (< 1-year) have shown the benefits of facility-based exercise training on physical function and HRQL, but have not evaluated the effects on metabolic risk factors. It remains unclear whether home-based exercise programs are feasible and can be sustained with sufficient adherence and exercise dose to have effects on PTMS. This protocol outlines the methodology of a randomized controlled trial of a partly-supervised home-based exercise program in lung (LTx) and liver (OLT) transplant recipients. OBJECTIVE 1) To evaluate the feasibility (i.e. recruitment rate, program adherence, attrition, safety, and participant satisfaction) of a 12-week individualized, home-based aerobic and resistance training program in LTx and OLT recipients initiated 12 to 18 months post-transplant; and 2) to assess estimates of intervention efficacy on metabolic risk factors, self-efficacy for exercise, and HRQL. METHODS 20 LTx and 20 OLT recipients with two or more cardio-metabolic risk factors at 12-18 months post-transplant will be randomized to an intervention group (home-based exercise training) or a control group. The intervention group will receive an individualized exercise prescription comprising aerobic and resistance training 3-5 times per week for 12 weeks. Participants will meet with a qualified exercise professional weekly (via videoconference) to guide exercise progression, provide support, and promote exercise self-efficacy. Participants in both study groups will receive one counselling session on healthy eating with a dietitian at the beginning of the intervention. For the primary aim, feasibility will be assessed through recruitment rate, program adherence, satisfaction, attrition, and safety. Secondary outcomes will be measured at baseline and 12-weeks, and include assessments of metabolic risk factors (i.e. insulin resistance, abdominal obesity, blood pressure, and cholesterol), HRQL, and exercise self-efficacy. Descriptive statistics will be used to summarize program feasibility and effect estimates (means and 95% confidence interval) for sample size calculations in future trials. RESULTS Enrollment for this study started in July 2021. It is estimated that the study period will be 18 months with data collection completed by December 2022. CONCLUSIONS A partly-supervised home-based, individually tailored exercise program that promotes aerobic and resistance training and exercise self-efficacy may prove to be an important intervention for improving the metabolic profile of LTx and OLT recipients with cardio-metabolic risk factors. Thus, characterizing the feasibility and effect estimates of home-based exercise constitutes the first step in the development of future clinical trials designed to reduce the high morbidity associated with PTMS. CLINICALTRIAL https://clinicaltrials.gov/ct2/show/NCT04965142

Adiponectin mRNA in adipose tissue and its association with metabolic risk factors in postmenopausal obese women

HORMONES ◽  
2013 ◽  
Vol 12 (1) ◽  
pp. 119-127 ◽  
Author(s):  
Sadashiv ◽  
Sunita Tiwari ◽  
Bhola Nath Paul ◽  
Sandeep Kumar ◽  
Abhijit Chandra ◽  
...  
Keyword(s):  
Risk Factors ◽  
Adipose Tissue ◽  
Metabolic Risk Factors ◽  
Metabolic Risk ◽  
Obese Women ◽  
Adiponectin Mrna

scholarly journals Adipose and Circulating CCL18 Levels Associate With Metabolic Risk Factors in Women

2016 ◽  
Vol 101 (11) ◽  
pp. 4021-4029 ◽  
Author(s):  
Daniel Eriksson Hogling ◽  
Paul Petrus ◽  
Hui Gao ◽  
Jesper Bäckdahl ◽  
Ingrid Dahlman ◽  
...  
Keyword(s):  
Risk Factors ◽  
Insulin Resistance ◽  
Risk Score ◽  
Metabolic Risk Factors ◽  
Immune Gene ◽  
Metabolic Risk ◽  
Model Assessment ◽  
M2 Macrophages ◽  
Obese Women ◽  
Human Adipocytes

Context: Cardiometabolic complications in obesity may be linked to white adipose tissue (WAT) dysfunction. Transcriptomic studies of Sc WAT have reported that CCL18, encoding the CC chemokine ligand 18 (CCL18), is increased in obesity/insulin resistance but its functional role is unknown. Objective: Our objectives were to determine if CCL18 is secreted from Sc WAT and if secreted and/or serum levels associate with metabolic phenotypes. We also planned to define the primary cellular source and if CCL18 exerts effects on adipocytes. Design: This is a cohort study. Setting: The study took place in an outpatient academic clinic. Participants: A total of 130 obese women scheduled for bariatric surgery and 35 nonobese controls were included. Methods: Insulin sensitivity was assessed by hyperinsulinemic euglycemic clamp or homeostasis model assessment. CCL18 was analyzed in serum/WAT incubates by ELISA. Effects of recombinant CCL18 was determined in cultures of primary human adipocytes and the monocyte cell line THP-1 differentiated into M0/M1/M2 macrophages. Main Outcome Measure: Association with metabolic risk factors was measured. Results: CCL18 was secreted from WAT and the levels correlated positively with insulin resistance, Adult Treatment Panel III risk score and plasma triglycerides, independent of body mass index and better than other established adipocytokines. In 80 obese women, S-CCL18 levels were significantly higher in insulin resistant compared with insulin sensitive subjects. In WAT CCL18 mRNA was expressed in macrophages and correlated positively with immune-related genes, particularly those enriched in M2 macrophages. While CCL18 increased cyto-/chemokine expression in M0/M2-THP-1 cells, human adipocytes showed no responses in vitro. Conclusions: Circulating and WAT-secreted CCL18 correlates with insulin resistance and metabolic risk score. Because CCL18 is macrophage-specific and associates with adipose immune gene expression, it may constitute a marker of WAT inflammation.

Sign in / Sign up

Export Citation Format

Share Document